NHS Awards Cytogenetics Tender to OGT
News Feb 04, 2014
Involving the cooperation of a number of health authorities, the tender’s comprehensive validation process sets an excellent example for future procurement procedures. The resulting two-year agreement covers a consortium of four UK NHS Genetics Labs (Bristol, Manchester, Salisbury and Sheffield), with an additional eight labs (Birmingham, Cambridge, Cardiff, Great Ormond Street, Leeds, Leicester, Nottingham and Oxford) able to take advantage of the agreed supply framework.
In order to assess the quality of the products, each Trust laboratory submitted a variety of samples for processing. OGT was successful against a number of alternative array providers with its CytoSure ISCA 8x60k platform, designed in collaboration with the International Collaboration for Clinical Genomics (ICCG)*, to deliver standardised, evidence-based designs to the cytogenetic research community. OGT was the only supplier whose product correctly identified all the genetic abnormalities tested. The success was attributed to a combination of the array and associated CytoSure Interpret Software performance, which delivers reliable and user-friendly data analysis, providing rapid access to meaningful results. This software is provided by OGT with all CytoSure arrays.
Leading the tender process was Mr Chris Wragg, BSc., FCRPath, Head of Molecular Cytogenetics at the Bristol Genetics Laboratory. He commented: “An exhaustive procurement and evaluation process was employed as, while we want to identify the most financially viable option, we can’t afford to compromise on quality. OGT was the only company able to deliver on quality, providing the best proposal, product and customer service. What we have achieved here is an excellent model for future procurements - it has delivered savings without compromising on quality.”
Dr Mike Evans, CEO of OGT said: “We are delighted with the result of this exceptionally well-run tender. It is a testament to our strong emphasis on not only the highest quality products and services but also customer support. We are pleased to continue our relationships with Bristol, Manchester, and Salisbury and are looking forward to welcoming Sheffield and the other Trusts to our group.”
*Formerly known as the International Standards for Cytogenomic Arrays (ISCA) Consortium.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Molecular Mechanism That Enable Neuronal Connections to Change With Development DiscoveredNews
Researchers from King's College London have discovered a molecular mechanism that enables neuronal connections to change through experience, thus fuelling learning and memory formation.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018